New drug ERX-315 enters first human tests for tough cancers
NCT ID NCT06533332
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing doses. The main goal is to find a safe dose and check for side effects, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ERX-315
What this could lead to
If it works, this could point toward a new treatment option for advanced solid tumors that no longer respond to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, focused on safety and dosing. It is too soon to know if ERX-315 will be effective or have manageable side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Research SA
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Icon Cancer Centre Adelaide
RECRUITINGAdelaide, South Australia, 5037, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Macquarie University Health
RECRUITINGRyde, New South Wales, 2109, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Kinghorn Cancer Center
RECRUITINGSydney, New South Wales, 2010, Australia
-
Westmead Hospital
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact Phone: •••-•••-••••
Contact